Fennec's CEO, Jeff Hackman, emphasized the company's strategic focus on expanding its market presence and enhancing its clinical data strategy. The company executed on its 2025 clinical data strategy to validate PEDMARK's effectiveness across new tumor types and patient populations through independent, institution-led research. The results from these initiatives have led to record patient enrollments and conversion rates, reflecting strong field execution.
In addition to revenue growth, Fennec completed an oversubscribed $42 million equity offering, which has bolstered its financial position. The company reported cash and cash equivalents of $36.7 million as of December 31, 2025, with no outstanding debt, positioning it well for future growth.
Fennec also announced positive topline results from an investigator-initiated clinical study of PEDMARK in Japan, aimed at reducing cisplatin-induced hearing loss. The company is pursuing registration in Japan and exploring partnership opportunities for PEDMARK.
Looking ahead, Fennec's management will host a conference call on March 24, 2026, at 8:30 a.m. ET to discuss these results and future strategies. The company remains committed to its mission of helping cancer patients protect their hearing while driving growth and operational excellence.
